Literature DB >> 17286750

Antiproliferative effects of melatonin on the growth of rat pituitary prolactin-secreting tumor cells in vitro.

Quan-Hui Yang1, Jian-Ning Xu, Rong-Kun Xu, Shiu-Fun Pang.   

Abstract

Earlier studies showed that melatonin reduced the growth of 17-beta-estradiol (E(2))-induced rat pituitary prolactin-secreting tumor (prolactinoma) in vivo. The mechanisms of melatonin's inhibitory action on the prolactin-secreting tumor were further explored by investigating the in vitro effects of melatonin on the growth of pituitary prolactin-secreting tumor cells. Primary cultured prolactinoma cells from E(2)-induced rat pituitary prolactin-secreting tumor were treated with 10(-5), 10(-4) or 10(-3) m melatonin for 5 days. Apoptosis was evaluated using flow cytometry and the TdT-mediated dUTP nick-end labeling (TUNEL) method. In addition, cell viability was analyzed by (3,4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. It was found that incubation of prolactinoma cells with 10(-5), 10(-4) or 10(-3) m melatonin for 5 days inhibited cell growth and increased cell apoptosis. Furthermore, melatonin increased caspase-3 activity, Bax mRNA expression, and cytochrome c protein expression. Conversely, Bcl-2 mRNA expression and mitochondrial membrane potential were inhibited by melatonin treatment. Our results further suggest that melatonin inhibits tumor growth by inducing apoptosis of rat pituitary prolactin-secreting tumor directly via the damage of mitochondria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17286750     DOI: 10.1111/j.1600-079X.2006.00403.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  8 in total

Review 1.  Melatonin as an anti-inflammatory agent in radiotherapy.

Authors:  M Najafi; A Shirazi; E Motevaseli; A H Rezaeyan; A Salajegheh; S Rezapoor
Journal:  Inflammopharmacology       Date:  2017-03-02       Impact factor: 4.473

Review 2.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

3.  A Comparison of B16 Melanoma Cells and 3T3 Fibroblasts Concerning Cell Viability and ROS Production in the Presence of Melatonin, Tested Over a Wide Range of Concentrations.

Authors:  Maria Angeles Bonmati-Carrion; Nuria Alvarez-Sánchez; Rüdiger Hardeland; Juan Antonio Madrid; Maria Angeles Rol
Journal:  Int J Mol Sci       Date:  2013-02-14       Impact factor: 5.923

4.  Melatonin as an antioxidant and its semi-lunar rhythm in green macroalga Ulva sp.

Authors:  Ofir Tal; Abraham Haim; Orna Harel; Yoram Gerchman
Journal:  J Exp Bot       Date:  2011-01-10       Impact factor: 6.992

5.  The Evaluation and Comparison of Transcriptionally Targeted Noxa and Puma Killer Genes to Initiate Apoptosis Under Cancer-Specific Promoter CXCR1 in Hepatocarcinoma Gene Therapy.

Authors:  Shahryar Khoshtinat Nikkhoi; Hedieh Heydarzadeh; Saeed Ranjbar; Fatemeh Salimi; Masoud Aghaeifard; Seyed Moayed Alavian; Azadeh Reshadmanesh
Journal:  Hepat Mon       Date:  2016-09-19       Impact factor: 0.660

Review 6.  Mitochondrial Dysfunction Pathway Networks and Mitochondrial Dynamics in the Pathogenesis of Pituitary Adenomas.

Authors:  Na Li; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-09       Impact factor: 5.555

7.  Role of Calcium Signals on Hydrogen Peroxide-Induced Apoptosis in Human Myeloid HL-60 Cells.

Authors:  Ignacio Bejarano; Javier Espino; David González-Flores; Javier G Casado; Pedro C Redondo; Juan A Rosado; Carmen Barriga; José A Pariente; Ana B Rodríguez
Journal:  Int J Biomed Sci       Date:  2009-09

8.  Magmas overexpression inhibits staurosporine induced apoptosis in rat pituitary adenoma cell lines.

Authors:  Federico Tagliati; Teresa Gagliano; Erica Gentilin; Mariella Minoia; Daniela Molè; Ettore C Delgi Uberti; Maria Chiara Zatelli
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.